MedTrace Logo

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

NCT04071574 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-05-09

No results posted yet for this study

Summary

The study will describe the effectiveness of ovarian stimulation in correlation with female infertility causes in a Lebanese population: a comparative study using 5 protocols of ovulation induction (treatment with "A" gonadotropins alone, "B" short GnRH agonist, "C" multiple-dose GnRH antagonist, "D" long GnRH agonist and "E" combined protocol of GnRH antagonist and agonist) and the outcomes of ICSI. This comparative study will help clinicians to select the relevant protocol of ovarian stimulation related to the female infertility disorders.

Conditions

  • Female Infertility
  • Female Infertility Due to Ovulatory Disorder
  • Premature Ovarian Failure
  • Polycystic Ovary Syndrome
  • Female Infertility of Tubal Origin
  • Ectopic Pregnancy
  • Salpingitis
  • Female Infertility Due to Tubal Block
  • Female Infertility Due to Tubal Occlusion
  • Hydrosalpinx
  • Female Infertility - Cervical/Vaginal
  • Female Infertility Endocrine
  • Endometriosis
  • Fibroids
  • Congenital Uterine Anomaly
  • Infections Uterine
  • Female Infertility of Other Origin

Interventions

DRUG

Human Chorionic Gonadotropin (hCG)

Administration of hCG (10.000IU) for ovulation triggering

DRUG

Gonadotropins

Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)

DRUG

GNRH-A Triptorelin

Administration of Triptorelin (0.1mg/day)

DRUG

GnRH antagonist

Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)

Sponsors & Collaborators

  • Lebanese University

    lead OTHER

Principal Investigators

  • Nehman Makdissy, Professor · Lebanese University

  • Samar El Hamoui, Dr · Lebanese University

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-01
Primary Completion
2019-08-22
Completion
2023-05-05

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071574 on ClinicalTrials.gov